News

AGNC Investment Corp.: March Dividend Update for Shareholders

AGNC Investment Corp.: March Dividend Update for Shareholders

AGNC Investment Corp. Declares Monthly Dividend for Shareholders

AGNC Investment Corp. declared a monthly cash dividend of $0.12 per share for March 2025. This announcement reflects the company's commitment to returning value to its shareholders. The Board of Directors takes significant pride in maintaining this dividend, ensuring that stockholders share in the profitability of the company's activities.

Dividend Details

The announced dividend will be payable on April 9, 2025. This payment is dedicated to stockholders of record as of March 31, 2025. Providing a stable income stream through dividends is integral to AGNC's financial strategy, demonstrating its ongoing commitment to shareholder value.

About AGNC Investment Corp.

Founded in 2008, AGNC Investment Corp. specializes in investing in Agency residential mortgage-backed securities (Agency MBS). These investments come with guarantees against credit losses by Fannie Mae, Freddie Mac, or Ginnie Mae. The company strategically finances its Agency MBS assets primarily through repurchase agreements, using dynamic risk management strategies to safeguard its portfolio against market risks and fluctuating interest rates.

Track Record of Dividends

AGNC has established a commendable history of delivering substantial long-term returns to its investors. Since its inception, the company has disbursed more than $14 billion in common stock dividends to its shareholders. This impressive figure highlights AGNC's role as a significant provider of private capital within the U.S. residential housing market, with a dedicated team experienced in managing mortgage assets effectively through various market conditions.

Contact Information

For any inquiries or more information, investors may reach out to the Investor Relations department at (301) 968-9300 or via email at IR@AGNC.com.

Frequently Asked Questions

What is the announced dividend for March 2025?

AGNC Investment Corp. has declared a cash dividend of $0.12 per share for March 2025.

When will the dividend be payable?

The dividend is scheduled to be paid on April 9, 2025.

Who qualifies for the dividend payment?

Stockholders of record as of March 31, 2025, will qualify for the dividend payment.

How long has AGNC Investment Corp. been in operation?

AGNC Investment Corp. was founded in 2008 and has been operating for many years, focusing on Agency MBS investments.

What is the company's primary investment strategy?

AGNC invests primarily in Agency residential mortgage-backed securities, using strategic financing and risk management techniques to protect its assets.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Huawei Introduces Innovative Wearables for Enhanced Connectivity

Updated Category News Views 293

Huawei Unveils Next-Generation Wearables and Tablets At a much-anticipated event, Huawei Consumer Business Group (CBG) revealed a thrilling array of new products. This launch showcased a strong emphasis on trendy wearables and sophisticated tablets, highlighting the brand's dedication to innovation and a user-friendly design. Chic Wearables for Style and Utility Among the...

Continue Reading
Investigating Barnes & Noble Education: Shareholder Rights Explained

Updated Category News Views 155

Understanding the Investigation of Barnes & Noble Education In a proactive move for investors, the law firm Bragar Eagel & Squire, P.C. is currently investigating Barnes & Noble Education, Inc. (BNED). This investigation aims to determine whether the company potentially breached federal securities laws or engaged in unlawful business practices that could lead to...

Continue Reading
Bailey Kennedy Achieves Landmark Legal Win for Talisman Group

Updated Category News Views 171

Bailey Kennedy Achieves Legal Victory for Talisman Group Judge Rules LNW Violated Talisman's Distribution Agreement by Marketing Competing Game In a significant legal development, Bailey Kennedy, LLP has successfully represented The Talisman Group, LLC, the innovative minds behind EZ Baccarat. The firm has recently triumphed in a legal dispute against LNW Gaming, Inc.,...

Continue Reading
Join the Class Action Lawsuit Against Ardelyx, Inc. Now

Updated Category News Views 49

Join the Class Action Lawsuit Against Ardelyx, Inc. Attention Ardelyx, Inc. investors! There's an important class action lawsuit underway, and this is your opportunity to get involved. Bronstein, Gewirtz & Grossman, LLC, a respected law firm known for its dedication to investor advocacy, has announced a class action case involving Ardelyx, Inc. (NASDAQ: ARDX) and certain...

Continue Reading
Aileron Therapeutics Unveils Q3 2024 Financial Performance

Updated Category News Views 97

Aileron Therapeutics Reports Impressive Q3 2024 Financial Results Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical company committed to developing innovative medicines for orphan pulmonary diseases, has recently showcased significant progress with their third-quarter financial results. This quarter has been marked by promising advancements in clinical trials...

Continue Reading